202 related articles for article (PubMed ID: 3926306)
1. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1985 Aug; 45(8):3642-5. PubMed ID: 3926306
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
Fracasso PM; Sartorelli AC
Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
[TBL] [Abstract][Full Text] [Related]
3. Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1989 Jun; 49(12):3310-3. PubMed ID: 2470504
[TBL] [Abstract][Full Text] [Related]
4. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells.
Kennedy KA; Rockwell S; Sartorelli AC
Cancer Res; 1980 Jul; 40(7):2356-60. PubMed ID: 7388797
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies of porfiromycin as an adjunct to radiotherapy.
Rockwell S; Keyes SR; Sartorelli AC
Radiat Res; 1988 Oct; 116(1):100-13. PubMed ID: 3186923
[TBL] [Abstract][Full Text] [Related]
6. Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1987 Nov; 47(21):5654-7. PubMed ID: 3664473
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.
Keyes SR; Heimbrook DC; Fracasso PM; Rockwell S; Sligar SG; Sartorelli AC
Adv Enzyme Regul; 1985; 23():291-307. PubMed ID: 3934922
[TBL] [Abstract][Full Text] [Related]
8. Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics.
Pritsos CA; Keyes SR; Sartorelli AC
Cancer Biochem Biophys; 1989 Oct; 10(4):289-98. PubMed ID: 2559790
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo.
Rockwell S; Keyes SR; Sartorelli AC
Anticancer Res; 1989; 9(4):817-20. PubMed ID: 2479329
[TBL] [Abstract][Full Text] [Related]
10. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells.
Marshall RS; Rauth AM
Cancer Res; 1988 Oct; 48(20):5655-9. PubMed ID: 3167822
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1985 Jan; 45(1):213-6. PubMed ID: 2578093
[TBL] [Abstract][Full Text] [Related]
12. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics.
Pritsos CA; Sartorelli AC
Cancer Res; 1986 Jul; 46(7):3528-32. PubMed ID: 3011250
[TBL] [Abstract][Full Text] [Related]
13. Preferential kill of hypoxic EMT6 mammary tumor cells by the bioreductive alkylating agent porfiromycin.
Sartorelli AC; Belcourt MF; Hodnick WF; Keyes SR; Pritsos CA; Rockwell S
Adv Enzyme Regul; 1995; 35():117-30. PubMed ID: 7572339
[TBL] [Abstract][Full Text] [Related]
14. Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions.
Hughes CS; Irvin CG; Rockwell S
Cancer Commun; 1991 Feb; 3(2):29-35. PubMed ID: 1899798
[TBL] [Abstract][Full Text] [Related]
15. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
16. Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo.
Rockwell S
J Natl Cancer Inst; 1983 Oct; 71(4):765-71. PubMed ID: 6413743
[TBL] [Abstract][Full Text] [Related]
17. Interactions of BMS-181174 and radiation: studies with EMT6 cells in vitro and in solid tumors.
Rockwell S; Kelley M
Radiother Oncol; 1996 Apr; 39(1):65-71. PubMed ID: 8735495
[TBL] [Abstract][Full Text] [Related]
18. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
[TBL] [Abstract][Full Text] [Related]
19. Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation.
Holden SA; Herman TS; Teicher BA
Radiother Oncol; 1990 May; 18(1):59-70. PubMed ID: 2113698
[TBL] [Abstract][Full Text] [Related]
20. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.
Keyes SR; Fracasso PM; Heimbrook DC; Rockwell S; Sligar SG; Sartorelli AC
Cancer Res; 1984 Dec; 44(12 Pt 1):5638-43. PubMed ID: 6437671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
